Hadden J W, Coffey R G
Recent Results Cancer Res. 1980;75:162-4. doi: 10.1007/978-3-642-81491-4_25.
BM 12,531 (azimexon) is an experimental immunomodulating agent which augments cellular immune responses in vivo. This study indicates that BM 12,531, while not directly mitogenic for human peripheral blood lymphocytes nor guinea pig peritoneal macrophages, potentiates the proliferative effects of phytohemagglutinin and a lymphokine, respectively. The optimal effects (0.001--0.01 microgram/ml) are somewhat greater in magnitude than those of levamisole. Unlike levamisole, BM 12,531 has no effect on cyclic 3',5' GMP levels or on guanylate cyclase activity of lymphocytes. The data suggest that both the thymus-derived lymphocyte and the monocyte-derived macrophage are cell targets of BM 12,531 action at concentrations achievable in vivo.
BM 12531（阿齐美克松）是一种实验性免疫调节剂，可增强体内细胞免疫反应。本研究表明，BM 12531虽然对人外周血淋巴细胞和豚鼠腹腔巨噬细胞无直接促有丝分裂作用，但分别增强了植物血凝素和一种淋巴因子的增殖作用。最佳作用浓度（0.001 - 0.01微克/毫升）在程度上比左旋咪唑略强。与左旋咪唑不同，BM 12531对淋巴细胞的环3',5'-鸟苷酸水平或鸟苷酸环化酶活性无影响。数据表明，在体内可达到的浓度下，胸腺来源的淋巴细胞和单核细胞来源的巨噬细胞都是BM 12531作用的细胞靶点。
